New Clinical Trial Available for Myelofibrosis Patients

Actuate Therapeutics Inc. is recruiting patients for Actuate 1901: 9-ING-41, a phase 2 study that will study its efficacy in patients with advanced MF.

Official Title: Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis

Detailed Description: 9-ING-41 is a first-in-class, intravenously administered, maleimide-based, small molecule, potent selective GSK-3β inhibitor with significant pre-clinical and clinical anticancer activity. In the ongoing Actuate 1801 study in a cohort of over 90 patients with advanced refractory malignancies, 9-ING-41 has exhibited no significant toxicity, including no myelosuppression, and significant anti-tumor activity. 9-ING-41 also has a significant pre-clinical ability to reverse pathologic fibrosis in multiple models of pulmonary and pleural fibrosis. Reversal of fibrosis by an anti-fibrotic agent in patients with advanced myelofibrosis (MF) has recently been demonstrated to be of clinical benefit. This Phase 2 study is designed to evaluate the efficacy of 9-ING-41, as a single agent or in combination with Ruxolitinib, in patients with advanced, poor prognosis MF.

Click here to learn more

 

 

Click the links below to learn more about additional MPN clinical trials & studies

MPN Clinical Trials
Clinical Trials: What You Need to Know
Participate in Research

1/7/2020

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe